heart failure with midrange ejection fraction
Conditions
Interventions
Experimental group:empagliflozin 10mg every day
control group:according to guidelines
Sponsors
Cardiology department of China-Japan friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years, gender is not limited; 2.Confirmed HFmrEF, according to the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure, meets the following three criteria: symptoms of heart failure (NYHAII-IV) and/or signs,NTproBNP>=400pg/mL,40%<=LVEF<50%; 3.Signed Informed Consent.
Exclusion criteria
Exclusion criteria: 1.Known cardiomyopathy, pericardium disease, valvular disease; 2.The primary disease (coronary heart disease, hypertension, diabetes, etc.)is unstable ; 3.Hypotension or other conditions that can not tolerate the study medicine ; 4.Contraindications for cardiopulmonary exercise testing including but not limited to, left main stenosis, acute heart failure, moderate to severe valve stenosis, hypertrophy cardiomyopathy, outflow tract stenosis, severe arrhythmia, acute pulmonary embolism, aortic dissection, acute myocarditis, acute pericarditis, infection affecting motor function, thyroid dysfunction, electrolyte disorder, uncontrolled hypertension, mental illness, etc; 5.Other conditions that are not suitable for clinical study include but are not limited to severe abnormal liver and kidney function (ALT or AST greater than three times the upper limit, estimated glomerular filtration rate less than or equal to 45 mL /min), pregnancy or breastfeeding, and life expectancy of malignant tumor less than 2 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak oxygen uptake; | — |
Secondary
| Measure | Time frame |
|---|---|
| N terminal pro B type natriuretic peptide;6 minute walk test; | — |
Countries
China
Contacts
Public ContactSun Yihong
China-Japan friendship Hospital
Outcome results
None listed